Flexion Therapeutics EBIT

The latest EBIT for FLXN is $-78M as of September 2021. That compares with $-110M in the prior-year period — up 27.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Flexion Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FLXN's EBIT moved from $-110M to $-78M — a 27.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Flexion Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, FLXN currently prints $-78M for EBIT, while the sector average sits near $23B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at Flexion Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-78M for FLXN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting FLXN's EBIT ($-78M), review year-over-year change from $-110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.